Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
TUKYSA® with ado-Trastuzumab Emtansine Boosts Survival in HER2+ Metastatic Breast Cancer
Thursday, December 07, 2023Seagen Inc today announced data from the Phase HERCLIMB clinical trial of TUKYSA in combination with the antibodydrug conjugate adotrastuzumab emtansine
IGC Pharma Announces Collaboration to Integrate AI into Clinical Trials
Thursday, December 07, 2023IGC Pharma Inc today announced an Artificial Intelligence collaboration with Los Andes Universitys Center for Research and Training in Artificial Intelligence The partnership aims to leverage Generative AI
Recipharm announces collaboration with Oz-UK to accelerate the development of low global warming potential pMDIs utilising HFA-152a propellant
Wednesday, December 06, 2023Global contract development and manufacturing organisation Recipharm has today announced a collaboration with OzUK a Contract Research Organisation and provider of solutions for respiratory RD
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program
Wednesday, December 06, 2023Arvinas Inc and Pfizer Inc today announced clinical data for vepdegestrant a novel oral PROteolysis TArgeting Chimera estrogen receptor degrader in combination with palbociclib
Neurocrine Biosciences Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Crinecerfont in Congenital Adrenal Hyperplasia
Wednesday, December 06, 2023Neurocrine Biosciences Inc today announced it received Breakthrough Therapy designation from the US Food and Drug Administration for crinecerfont in congenital adrenal hyperplasia
Roche Enters Into a Definitive Merger Agreement to Acquire Carmot Therapeutics, Including Three Clinical Stage Assets With Best-in-class Potential in Obesity and Diabetes
Tuesday, December 05, 2023Roche announced today the entry into a definitive merger agreement to acquire Carmot Therapeutics Inc a privately owned US company based in Berkeley California
Oxford Biomedica Signs Agreement to Acquire ABL Europe From Institut Mérieux, Consolidating Position as a Global Pure-play CDMO
Tuesday, December 05, 2023Oxford Biomedica plc a quality and innovationled cell and gene therapy CDMO today announces that it has entered into a sale and purchase agreement
Kindeva Drug Delivery and Orbia Fluorinated Solutions (Koura) Announce Collaboration for Low GWP Propellant Conversion
Tuesday, December 05, 2023Kindeva Drug Delivery Kindeva a leading global contract development and manufacturing organization CDMO focused on drugdevice combination products and Orbia Advance Corporation SAB de CV Fluorinated Solutions business Koura
First Patient Dosed in European Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent
Monday, December 04, 2023Telix Pharmaceuticals Limited today announces that the first patient has been dosed in a named patient program in the Netherlands for its investigational positron emission
Scantox acquires QPS Austria's Neuropharmacology Division
Saturday, December 02, 2023Today Scantox together with its majority owner Impilo has agreed to acquire the neuropharmacology division of QPS Austria GmbH ultimately owned by QPS Holdings LLC QPS Neuro is a leading drug discovery Contract Research Organization
